{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Condition&page=32", "query": { "condition": "Condition", "page": 32 }, "page_size": 10 }, "pagination": { "page": 32, "page_size": 10, "total_count": 152831, "total_pages": 15284, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Condition&page=33&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Condition&page=31&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T23:52:30.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04860830", "title": "CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Iclepertin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 609, "start_date": "2021-08-09", "completion_date": "2024-11-20", "has_results": true, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 24, "location_summary": "Anaheim, California • Culver City, California • Los Angeles, California + 19 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pico Rivera", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04860830" }, { "nct_id": "NCT02707328", "title": "Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreas Cancer", "Pancreatic Cancer", "Adenocarcinoma of the Pancreas", "Pancreas Adenocarcinoma", "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "CyberKnife", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "The Cooper Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2015-01", "completion_date": "2017-11-10", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 1, "location_summary": "Camden, New Jersey", "locations": [ { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02707328" }, { "nct_id": "NCT05294328", "title": "Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Presbyopia", "Refractive Errors", "Eye Diseases" ], "interventions": [ { "name": "Aceclidine+Brimonidine combination ophthalmic solution", "type": "DRUG" }, { "name": "Aceclidine ophthalmic solution", "type": "DRUG" }, { "name": "Vehicle Proprietary Ophthalmic Solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "LENZ Therapeutics, Inc", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "45 Years to 75 Years" }, "enrollment_count": 68, "start_date": "2022-05-05", "completion_date": "2022-09-10", "has_results": true, "last_update_posted_date": "2024-09-05", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 5, "location_summary": "Glendale, California • Indianapolis, Indiana • Andover, Massachusetts + 2 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Andover", "state": "Massachusetts" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05294328" }, { "nct_id": "NCT01533428", "title": "A Study to Evaluate Efficacy and Safety of a Single Application of Capsaicin 8%Transdermal Delivery System Compared to Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Peripheral Neuropathy", "Pain" ], "interventions": [ { "name": "Capsaicin 8%", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 369, "start_date": "2012-02", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-11-04", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 29, "location_summary": "Anniston, Alabama • Fresno, California • Long Beach, California + 24 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Fresno", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01533428" }, { "nct_id": "NCT00365300", "title": "Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastroesophageal Reflux" ], "interventions": [ { "name": "pantoprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "28 Days", "maximum_age": "11 Months", "sex": "ALL", "summary": "28 Days to 11 Months" }, "enrollment_count": 129, "start_date": "2006-09", "completion_date": "2007-11", "has_results": true, "last_update_posted_date": "2010-05-04", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 38, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365300" }, { "nct_id": "NCT05352828", "title": "Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Classical Hodgkin Lymphoma", "Hodgkin Disease Refractory", "Hodgkin Disease Recurrent" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Autologous CD30.CAR-T", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tessa Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 15, "start_date": "2022-07-25", "completion_date": "2037-12-15", "has_results": false, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 5, "location_summary": "Duarte, California • Miami, Florida • Chapel Hill, North Carolina + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05352828" }, { "nct_id": "NCT04342728", "title": "Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "COVID", "Corona Virus Infection" ], "interventions": [ { "name": "Ascorbic Acid", "type": "DIETARY_SUPPLEMENT" }, { "name": "Zinc Gluconate", "type": "DIETARY_SUPPLEMENT" }, { "name": "Ascorbic Acid and Zinc Gluconate", "type": "DIETARY_SUPPLEMENT" }, { "name": "Standard of Care", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "The Cleveland Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 214, "start_date": "2020-04-08", "completion_date": "2021-02-11", "has_results": false, "last_update_posted_date": "2021-02-16", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 2, "location_summary": "Weston, Florida • Cleveland, Ohio", "locations": [ { "city": "Weston", "state": "Florida" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04342728" }, { "nct_id": "NCT02371200", "title": "Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Epilepsy", "Generalized Tonic-Clonic Seizures" ], "interventions": [ { "name": "Brain Sentinel Seizure Detection and Warning System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Brain Sentinel", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "2 Years to 99 Years" }, "enrollment_count": 13, "start_date": "2015-04", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 2, "location_summary": "Charleston, South Carolina • San Antonio, Texas", "locations": [ { "city": "Charleston", "state": "South Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02371200" }, { "nct_id": "NCT05259800", "title": "Peppermint Oil for Urinary Retention", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Urinary Retention" ], "interventions": [ { "name": "Peppermint oil vapors", "type": "OTHER" }, { "name": "Mineral Oil", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "TriHealth Inc.", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2021-10-05", "completion_date": "2025-04-01", "has_results": true, "last_update_posted_date": "2025-08-29", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259800" }, { "nct_id": "NCT02675400", "title": "Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Attention Deficit/Hyperactivity Disorder (ADHD)" ], "interventions": [ { "name": "Vyvanse", "type": "DRUG" }, { "name": "Behavioral Parent Training", "type": "BEHAVIORAL" }, { "name": "Methylphenidate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "21 Years to 55 Years · Male only" }, "enrollment_count": 19, "start_date": "2015-12", "completion_date": "2018-08-31", "has_results": false, "last_update_posted_date": "2018-09-12", "last_synced_at": "2026-10-23T23:52:30.817Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02675400" } ] }